Back to results
US 8,618,172 B2Granted
Galenical formulations of organic compounds
AssigneeNovartis AG
InventorMatthias Willmann
Life of this patent
Estimating the term…
Abstract
The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of HCTZ and a hydrophilic filler selected from the group a carbohydrate or combinations thereof, e.g. sugars, sugar alcohols and starches or combinations of these.
Claims14
A solid oral dosage form comprising
- (i) 28-44% aliskiren, or a pharmaceutically acceptable salt thereof, by weight based on the total weight of the oral dosage form;
- (ii) 1.4-5.5% hydrochlorothiazide by weight based on the total weight of the oral dosage form;
- and
- (iii) 5-25% carbohydrate hydrophilic filler by weight based on the total weight of the oral dosage form, wherein the carbohydrate hydrophilic filler is a mixture of wheat starch and lactose;
- (iv) 22-33% microcrystalline cellulose, by weight based on the total weight of the oral dosage form;
- (v) 9-13% crosslinked polyvinylpyrrolidone, by weight based on the total weight of the oral dosage form;
- (vi) 0.6-1.8% colloidal silicon dioxide, by weight based on the total weight of the oral dosage form;
- (vii) 0.4-1.8% talc, by weight based on the total weight of the oral dosage form;
- (viii) 1-1.5% magnesium stearate, by weight based on the total weight of the oral dosage form;
- and
- (ix) 2.1-3.2% polyvinylpyrrolidone, by weight based on the total weight of the oral dosage form.
8 more elements
Dependencies are inferred from the claim text.